Publications by authors named "Sindy Kim"

Claim this Profile
A
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.
Richard S Finn, Hope S Rugo, Javier Cortes, Sibylle Loibl, Grace Foley, Sindy Kim

Target Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer.
Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang, Kathleen M Aguilar

Future Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer.
Dennis J Slamon, Véronique Diéras, Hope S Rugo, Nadia Harbeck, Seock-Ah Im, Sindy Kim

J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Hope S Rugo, Seock-Ah Im, Anil A Joy, Yaroslav Shparyk, Janice M Walshe, Sindy Kim

Future Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer.
Angela DeMichele, Nicholas Robert, Connie Chen, Sindy Kim, Zhe Zhang

Target Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Sindy T Kim

J Clin Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India.
Sherene Loi, Christos S Karapetis, Nicole McCarthy, Catherine Oakman, Andrew Redfern, Sindy Kim

Asia Pac J Clin Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Hope S Rugo, Seock-Ah Im, Anil A Joy, Yaroslav Shparyk, Janice M Walshe, Sindy Kim

Breast· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Massimo Cristofanilli, Hope S Rugo, Seock-Ah Im, Dennis J Slamon, Nadia Harbeck, Sindy Kim

Clin Cancer Res· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data of Palbociclib in Combination With Endocrine Therapy for the Treatment of Metastatic Breast Cancer in Men.
Albert L Kraus, Michelle Yu-Kite, Jack Mardekian, Matthew J Cotter, Sindy Kim

Clin Pharmacol Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of palbociclib in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2.
Karen Gelmon, Janice M Walshe, Reshma Mahtani, Anil A Joy, Meghan Karuturi, Sindy Kim

Breast· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).
Richard S Finn, Katalin Boer, Igor Bondarenko, Ravindranath Patel, Tamas Pinter, Sindy Kim

Breast Cancer Res Treat· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib plus endocrine therapy in older women with HR+/HER2- advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies.
Hope S Rugo, Nicholas C Turner, Richard S Finn, Anil A Joy, Sunil Verma, Sindy Kim

Eur J Cancer· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Ruben Niesvizky, Ashraf Z Badros, Luciano J Costa, Scott A Ely, Seema B Singhal, Sindy T Kim

Leuk Lymphoma· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.
Richard S Finn, John P Crown, Johannes Ettl, Marcus Schmidt, Igor M Bondarenko, Sindy T Kim

Breast Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study.
Richard S Finn, John P Crown, Istvan Lang, Katalin Boer, Igor M Bondarenko, Sindy T Kim

Lancet Oncol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.
Charles S Harmon, Samuel E DePrimo, Robert A Figlin, Gary R Hudes, Thomas E Hutson, Sindy T Kim

Cancer Chemother Pharmacol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyzing the pivotal trial that compared sunitinib and IFN-α in renal cell carcinoma, using a method that assesses tumor regression and growth.
Wilfred D Stein, Julia Wilkerson, Sindy T Kim, Xin Huang, Robert J Motzer

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
Radj Gervais, John D Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, Sindy T Kim

Lung Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
Elisabeth I Heath, George R Blumenschein, Roger B Cohen, Patricia M Lorusso, Noelle K Loconte, Sindy T Kim

Cancer Chemother Pharmacol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Robert J Motzer, Gary R Hudes, Michelle S Ginsberg, Michael S Baum, Charles S Harmon, Sindy T Kim

Am J Clin Oncol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
Robert J Motzer, Thomas E Hutson, Piotr Tomczak, M Dror Michaelson, Ronald M Bukowski, Sindy T Kim

J Clin Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using the Rasch model to validate and enhance the interpretation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index--Disease-Related Symptoms scale.
Xuemei Luo, Joseph C Cappelleri, David Cella, Jim Z Li, Claudie Charbonneau, Sindy T Kim

Value Health· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa.
David Cella, Joseph C Cappelleri, Andrew Bushmakin, Claudie Charbonneau, Jim Z Li, Sindy T Kim

J Oncol Pract· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
Robert J Motzer, Ronald M Bukowski, Robert A Figlin, Thomas E Hutson, M Dror Michaelson, Sindy T Kim

Cancer· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis